查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844118

T细胞疗法市场按最终用户、细胞来源、适应症、疗法类型和生产模式划分—2025-2032年全球预测

T-Cell Therapy Market by End User, Cell Source, Indication, Therapy Type, Manufacturing Model - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，T 细胞疗法市场规模将达到 478.2 亿美元，复合年增长率为 21.83%。

主要市场统计数据
基准年 2024 98.5亿美元
预计年份：2025年 120.3亿美元
预测年份：2032年 478.2亿美元
复合年增长率 (%) 21.83%

临床检验、生产製造成熟和医疗保健系统采纳如何影响现代 T 细胞疗法？

T细胞疗法已从实验科学发展成为先进免疫疗法的关键支柱，彻底改变了临床医生和研发人员治疗癌症、感染疾病和自体免疫疾病的方式。过去十年间，细胞工程、载体设计和生产流程的进步，以及反覆的临床验证，使得细胞产品从小众临床实验药物转变为具有明确监管管道和商业化策略的成熟疗法。

关键挑战在于如何在保持科学研究动能的同时，克服与可扩展性、成本控制和全球供应链韧性相关的实际限制。随着研发人员不断改进抗原靶向性和持久性特征，医疗系统和支付方必须改善其临床价值和长期安全性的评估框架。同时，在决定一种疗法的商业性命运方面，生产创新和策略伙伴关係与临床差异化同样至关重要。

因此，相关人员必须权衡近期业务决策与对平台技术、人才队伍和监管参与的长期投资。本执行摘要的其余部分概述了变革性转变、细分资讯、区域动态以及领导者可用于加速临床应用和永续商业化的实用建议。

基因工程、自动化製造和适应性监管的融合正在加速向平台主导T细胞疗法生态系统的转型。

在科学突破和营运规模化共同推动下，T细胞疗法领域正经历变革性的转变。基因编辑工具和新一代受体工程技术拓展了可安全靶向的抗原类型，使得针对以往难以治疗的适应症的个人化治疗成为可能。同时，同种异体疗法和现成T细胞製剂的成熟正在改变人们对治疗时间和库存管理的预期，进而影响研发者、製造外包和临床试验中心之间的关係。

製造业正从手工操作、以患者为中心的生产流程转变为融合自动化、封闭式系统和模组化生产线的混合模式。这种运作模式的演变减少了人为因素的影响，缩短了批次週转时间，并能够支援更广泛的临床计画。此外，生产数据和品质系统的数位化提高了可追溯性和合规性，同时也为应用预测分析优化产量比率创造了机会。

监管机构的参与和支付方的互动是另一个变革的驱动力。监管机构越来越接受适应性试验设计和真实世界证据作为安全性和有效性数据的补充来源。同时，支付方要求提供能够将临床效用与持久疗效和经济价值结合的证据。这些压力促使研发人员设计证据产生策略，将随机数据与註册研究和卫生经济学模型结合。这些科学、管理和商业性的转变正在加速从单一产品创新向平台主导的可持续治疗生态系统的转变。

2025年贸易政策的累积影响加剧了供应链的敏感性，并促使製造模式和临床实验供应计画发生策略性转变。

美国2025年实施的关税和贸易政策调整产生了累积影响，波及整个T细胞疗法价值链，影响到原料投入、生产决策和国际合作。病毒载体、一次性耗材和专用试剂等关键原料的采购通常涉及跨境供应商。关税增加了到岸成本，迫使企业重新评估供应商选择、库存策略和近期资本配置。

为此，许多开发商和受託製造製造商重新评估了其生产模式，权衡受託製造伙伴关係的优势与自主生产的战略控制权。经营全球供应链网路的公司增加了缓衝库存，并实现了供应商多元化，以缓解关税造成的价格波动。同时，一些公司加快了关键生产流程的在地化进程，将生产环节转移到贸易协定更稳定的国家和地区，虽然这带来了物流和监管方面的复杂性，但也减轻了进口关税的影响。

在临床方面，关税带来的成本压力影响了检测供应计划和进度，尤其是依赖集中生产的多区域检测。申办方调整了受试者招募速度或采取了分散式生产策略，以维持检测的连续性。商业性，不断上涨的投入成本促使申办方与支付方就创新合约和风险分担机制展开更深入的讨论，以因应不断上涨的製造成本。总体而言，2025年关税的累积影响凸显了供应链对冲、灵活的生产布局以及积极的相关人员合作对于维持临床进展和商业性可行性的重要性。

跨临床环境、细胞来源、适应症、治疗方式和生产方案的深度细分智能，能够实现差异化的开发和商业策略。

细分市场分析揭示了不同临床环境、生技药品来源、治疗重点、治疗方式和交付模式的差异化策略需求。从终端使用者环境的角度来看，医院仍然是提供复杂自体培养通讯协定的核心，这些方案需要受控的住院环境和多学科支援；研究机构继续推动早期创新和转化科学；随着手术和支持性护理的日益标准化，专科诊所也越来越多地采用门诊通讯协定。

考虑细胞来源细分凸显了同种异体和自体疗法之间的根本权衡。自体构建体在监管方面有着悠久的历史先例，并能提供个人化的抗原识别，但需要针对特定患者的生产物流。相反，同种异体构建体具有扩大治疗规模和缩短疗程的潜力，但需要考虑免疫抗原性和移植情况，因此需要个别化的临床策略和生产控制。

适应症细分突显了不同疾病领域治疗重点和证据要求的差异。肿瘤治疗需要持久缓解和对急性毒性的谨慎管理，而感染疾病和自体免疫疾病则需要不同的疗效终点和安全性接受度。在自体免疫疾病中，多发性硬化症、干癣和类风湿性关节炎等疾病具有独特的病理生理标靶和患者群体，这些都会影响临床试验的设计。在感染疾病中，B型肝炎、C型肝炎和爱滋病需要客製化的病理学和免疫学终点。在肿瘤学领域，从白血病、淋巴瘤和多发性骨髓瘤等骨髓恶性肿瘤到乳癌、肺癌和黑色素瘤等固体癌，独特的肿瘤微环境限制都会影响细胞迁移和持久性。

依治疗方法类型细分，突显了CAR-T细胞疗法、TCR-T细胞疗法和TIL疗法在抗原辨识、生产复杂性和临床应用方面的差异。 CAR-T细胞疗法在血液系统骨髓恶性肿瘤中展现出强大的疗效，并依赖人工构建的受体；TCR疗法扩展了其抗原库，使其包含细胞内靶点；而TIL疗法则利用肿瘤驻留淋巴细胞来增强固态肿瘤的免疫抗原性。最后，按生产模式（将企业定位在契约製造和内部生产之间）进行细分，为企业在资本投资、品质体繫管理以及快速扩大生产规模以应对临床或商业性需求方面提供了策略选择框架。因此，每个细分维度都有助于确定研发投资、营运设计和打入市场策略的优先顺序。

全球各地不同的法规环境、支付方特征和生产能力将如何推动差异化的打入市场策略和供应链策略？

区域动态影响从临床开发到商业化和供应链组织的策略重点。在美洲，强大的临床试验基础设施、重点突出的医保报销谈判以及雄厚的生产能力有利于加速临床应用和早期商业化，但成本压力和区域医保报销差异要求企业提出清晰的价值主张和创新的定价策略。

欧洲、中东和非洲监管体系的多样性以及不同的卫生技术评估框架，使得针对特定区域的证据整合和支付方参与计画成为必要。该地区是合作研究的中心，拥有越来越多的细胞疗法製造地，为跨境临床试验网络和联合生产联盟提供了机会，但报销时间表往往会影响产品上市顺序和市场准入管道。

亚太地区的特点是製造业产能投资快速成长、临床试验活动活性化，以及监管方式的多样性，部分地区实施快速审批通道，而其他地区则尚处于起步阶段。在地化生产和监管协调能够创造竞争优势，尤其对于那些寻求缓解贸易相关成本压力并加快患者用药速度的公司而言更是如此。因此，每个地区都需要製定量身定制的产业计画，将监管预期、支付方环境、临床能力和供应链因素相结合，以支持业务的可持续扩张。

企业层面的竞争优势日益来自平台科学、可扩展製造以及积极主动地与支付方和监管机构互动等综合能力。

公司层级的关键竞争考察围绕着能力整合、伙伴关係策略和垂直整合决策展开，这些因素将决定其竞争定位。领先的临床阶段公司正透过将受体工程专业知识与其转化产品线相结合来拓展其适应症范围，而其他公司则专注于提升其平台的稳健性，以支援多个候选产品。受託製造公司正在超越纯粹的生产角色，转型为提供製程开发、分析服务和品质源于设计能力的策略伙伴，从而帮助申办方缩短临床试验时间。

研发公司、学术中心和生产供应商之间的策略伙伴关係日益普遍，从而能够共用载体优化、效力检测、冷冻保存技术等方面的专业知识。投资于模组化、自动化生产设备和数据整合品质系统的公司能够灵活地管理不同类型的治疗药物，并扩大自体和异体药物的生产规模。此外，积极与监管机构和支付方沟通并制定循证路径的公司，将在市场准入谈判中占据优势。

企业如何透过流程改善、供应链多元化和创新商业协议来应对服务成本挑战，也是实现差异化竞争的关键。那些能够平衡临床差异化和卓越营运的企业，更有能力从小批量临床供应过渡到可靠的商业分销，同时满足不断变化的监管要求。

一份实用的领导力指南，旨在协调製造自动化、供应链多元化、证据产生和相关人员参与，以加速转换和应用。

产业领导者应采取多管齐下的方法，将科学目标与实际操作结合。首先，应优先投资于製造自动化和封闭式系统製程开发，以降低变异性、减少对劳动力的依赖并加快交付速度。这项营运基础能够确保产品品质更加稳定，并支援对需求波动做出灵活响应。

第二，我们将实现关键投入品供应商网路的多元化，并实施策略性库存措施，以降低因贸易波动和关税造成的成本转移风险。同时，我们将评估关键製造流程的近岸外包和本地化，以降低物流复杂性，并提高对本地市场的应对力。第三，我们将推行实证医学策略，将随机数据与真实世界结果以及註册登记主导的纵向追踪研究相结合，以满足监管机构和支付方对持续效益的要求。

第四，在学术界、临床和生产製造生态系统中建立伙伴关係，以利用外部资源，同时维持对核心平台技术的策略控制。第五，儘早与监管机构和支付方进行迭代式沟通，以确定测试终点、卫生经济学模型和报销机制，使临床价值与永续定价一致。最后，透过制定基本契约框架和建立临床支援计划来加强商业性能力，从而促进在各种医疗环境中的应用。这些建议为应对复杂性、加速患者取得治疗方案和提高商业性可行性提供了蓝图。

一项透明的三管齐下的调查方法结合了专家访谈、临床和监管文件以及生产流程分析，从而提供可靠且可操作的见解。

本执行摘要的研究采用三角分析法，整合了第一手和第二手资料，以确保分析的严谨性和有效性。第一手资料包括对临床实验研究员、製造企业高管和监管顾问的结构化访谈，并辅以与支付方和医院管理人员的咨询会议，以了解营运和报销方面的观点。这些定性资讯与公开的监管文件、同行评审文献和行业披露资讯进行系统比对，以检验趋势并识别宣称的能力与实际营运绩效之间的差异。

数据分析整合了来自製造研讨会的流程层面洞察，以及来自临床註册研究和已发表研究的测试设计和终点评估。在条件允许的情况下，我们采用调查方法三角验证法，将访谈结果与文献证据和专家小组的回馈进行交叉比对。品管程序包括对主题性观察进行独立审查、专家检验技术论断，以及根据相关人员的回馈进行迭代改进。这种多层次的方法确保了结论既反映了当前技术水平，也反映了实际部署中遇到的运行限制。

将科学前景与营运需求结合，证明T细胞疗法的可持续商业化需要技术、监管和商业执行的整合。

T细胞疗法在现代医学中占据着变革性的地位，有望为肿瘤、感染疾病和自体免疫疾病等多种适应症提供持久的解决方案。儘管该领域能够带来临床突破，但也面临供应链、生产和医保报销等方面的现实挑战，这些挑战决定着患者获得治疗的速度。对于那些致力于将科学前景转化为持续的临床和商业性影响的机构而言，在细胞来源、治疗方法、生产模式和地理扩张等方面做出策略决策至关重要。

那些相关人员，很可能获得竞争优势。相反，那些低估临床、生产和商业领域整合挑战的利益相关者，则可能面临延迟市场上市和限制应用的风险。总之，T细胞疗法的持续成长需要持续的科学创新和价值链上严谨的执行。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 双靶向CAR-T细胞疗法的进展可提高肿瘤特异性和安全性
  • 整合 CRISPR 等基因编辑技术以增强 T 细胞的持久性和疗效
  • 新兴企业与製药巨头建立策略伙伴关係，加速T细胞疗法的商业化进程
  • 照护现场製造平台的出现将缩短CAR-T细胞的生产时间和降低成本。
  • 将T细胞疗法的应用范围从肿瘤治疗领域扩展到自体免疫感染疾病领域
  • 开发下一代可切换CAR-T细胞，实现可控活化以减轻细胞激素释放综合征
  • 人工智慧和机器学习在优化T细胞生产和患者选择方面的应用日益广泛。
  • 不断变化的监管环境为具有真实世界证据的T细胞疗法提供了快速核准通道。
  • 利用基因组编辑技术建构通用供体T细胞平台，以预防移植物抗宿主疾病风险。

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章：按最终用户分類的T细胞疗法市场

  • 医院
  • 研究所
  • 专科诊所

第九章 T细胞疗法市场：依细胞来源划分

  • 同种异体
  • 自体移植

第十章 依适应症分類的T细胞疗法市场

  • 自体免疫疾病
    • 多发性硬化症
    • 银屑病
    • 类风湿性关节炎
  • 感染疾病
    • B型肝炎
    • C型肝炎
    • HIV
  • 肿瘤学
    • 白血病
    • 淋巴瘤
    • 多发性骨髓瘤
    • 固态肿瘤
      • 乳癌
      • 肺癌
      • 黑色素瘤

第十一章 T细胞疗法市场按疗法类型划分

  • CAR-T细胞疗法
  • TCR T细胞疗法
  • TIL治疗

第十二章：依生产模式分類的T细胞疗法市场

  • 契约製造
  • 内部生产

第十三章：按地区分類的T细胞疗法市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 T细胞疗法市集（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国T细胞疗法市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Novartis AG
    • Kite Pharma, Inc.
    • Bristol-Myers Squibb Company
    • Janssen BIoTech, Inc.
    • Gilead Sciences, Inc.
Product Code: MRR-A26E0E5744D4

The T-Cell Therapy Market is projected to grow by USD 47.82 billion at a CAGR of 21.83% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.85 billion
Estimated Year [2025] USD 12.03 billion
Forecast Year [2032] USD 47.82 billion
CAGR (%) 21.83%

How clinical validation, manufacturing maturation, and health system adoption are collectively shaping the modern T-cell therapy landscape for near-term strategic planning

T-cell therapies have moved from experimental science to a critical pillar of advanced immunotherapy, reshaping how clinicians and developers approach treatment of oncology, infectious, and autoimmune conditions. Over the past decade, iterative clinical proof points combined with advances in cell engineering, vector design, and manufacturing processes have transitioned cellular products from niche investigational agents to therapies with defined regulatory pathways and commercialization strategies.

The industry now confronts a dual imperative: to sustain scientific momentum while solving practical constraints associated with scalability, cost management, and global supply chain resiliency. As developers refine antigen targeting and persistence profiles, healthcare systems and payers must evolve assessment frameworks for clinical value and long-term safety. Meanwhile, manufacturing innovations and strategic partnerships are becoming as decisive as clinical differentiation in determining a therapy's commercial fate.

Consequently, stakeholders must balance near-term operational decisions with longer-term investments in platform technologies, workforce capabilities, and regulatory engagement. The remainder of this executive summary synthesizes the transformative shifts, segmentation intelligence, regional dynamics, and pragmatic recommendations that leaders can leverage to accelerate clinical translation and sustainable commercialization.

Convergence of gene engineering, automated manufacturing, and adaptive regulatory engagement is accelerating the transition to platform-driven T-cell therapy ecosystems

The T-cell therapy landscape is undergoing transformative shifts driven by convergence of scientific breakthroughs and operational scaling. Gene editing tools and next-generation receptor engineering have expanded the kinds of antigens that can be safely targeted, enabling tailored approaches for previously intractable indications. Concurrently, the maturation of allogeneic strategies and off-the-shelf constructs is changing expectations around time-to-treatment and inventory management, which in turn alters the relationships between developers, contract manufacturers, and clinical sites.

Manufacturing has evolved from artisanal, patient-specific workflows to hybridized models that incorporate automation, closed systems, and modular production lines. This operational evolution reduces manual variability, compresses batch turnaround times, and enables capacity to support broader clinical programs. Furthermore, digitalization of production data and quality systems has improved traceability and regulatory readiness, while also creating opportunities to apply predictive analytics for yield optimization.

Regulatory engagement and payer interactions represent another axis of change. Authorities are increasingly receptive to adaptive trial designs and real-world evidence as complementary sources of safety and effectiveness data. At the same time, payers demand evidence that aligns clinical benefit with durable outcomes and economic value. These pressures are prompting developers to design evidence-generation strategies that blend randomized data with registries and health-economic modeling. In combination, these scientific, operational, and commercial shifts are accelerating a transition from single-product innovation to platform-driven, sustainable therapeutic ecosystems.

Cumulative trade policy effects in 2025 amplified supply chain sensitivities and prompted strategic shifts in manufacturing models and trial supply planning

The introduction of tariffs and trade policy adjustments in the United States during 2025 created a cumulative set of impacts that ripple through the T-cell therapy value chain, affecting inputs, manufacturing decisions, and international collaborations. Sourcing of critical raw materials such as viral vectors, single-use consumables, and specialized reagents often involves cross-border suppliers; tariffs increase landed costs and force organizations to reassess supplier selection, inventory strategies, and near-term capital allocation.

In response, many developers and contract manufacturers reevaluated their manufacturing models, weighing the benefits of contract manufacturing partnerships against the strategic control afforded by in-house production. Organizations operating global supply networks increased buffer inventories and diversified supplier bases to mitigate tariff-driven price volatility. At the same time, some companies accelerated localization of key production steps to jurisdictions with more stable trade arrangements, which created logistical and regulatory complexities but reduced exposure to import duties.

Clinically, tariff-driven cost pressures affected trial supply planning and timelines, particularly for multi-regional studies reliant on centralized manufacturing. Sponsors adjusted enrollment pacing or adopted decentralized manufacturing strategies to preserve trial continuity. Commercially, higher input costs intensified discussions with payers around innovative contracting and risk-sharing mechanisms that account for manufacturing cost inflation. Overall, the cumulative impact of tariffs in 2025 emphasized the need for supply chain hedging, flexible manufacturing footprints, and proactive stakeholder alignment to preserve both clinical momentum and commercial viability.

Deep segmentation intelligence across clinical settings, cell origins, indications, modalities, and manufacturing choices that informs differentiated development and commercial strategies

Segmentation analysis reveals differentiated strategic imperatives across clinical settings, biologic sourcing, therapeutic focus, modality, and operational delivery models. When viewing the market through the lens of end-user environments, hospitals remain central for delivering complex autologous protocols that require controlled inpatient settings and multidisciplinary support, whereas research institutes continue to drive early-phase innovation and translational science, and specialty clinics increasingly host outpatient-capable protocols as procedures and supportive care become more standardized.

Examining cell source segmentation underscores fundamental trade-offs between allogeneic and autologous approaches. Autologous constructs historically offered personalized antigen recognition with established regulatory precedents but required patient-specific manufacturing logistics. Conversely, allogeneic constructs promise scale and reduced time-to-treatment but introduce immunogenicity and engraftment considerations that necessitate distinct clinical strategies and manufacturing controls.

Indication segmentation highlights how therapeutic priorities and evidence requirements vary by disease area. Oncology programs demand durable remissions and careful management of acute toxicities, while infectious disease and autoimmune indications require different efficacy endpoints and safety tolerances. Within autoimmune diseases, conditions such as multiple sclerosis, psoriasis, and rheumatoid arthritis present distinct pathophysiologic targets and patient populations that influence trial design. For infectious diseases, hepatitis B, hepatitis C, and HIV each require tailored virologic and immunologic endpoints. Oncology indications span hematologic malignancies like leukemia, lymphoma, and multiple myeloma to solid tumors, where breast cancer, lung cancer, and melanoma each impose unique tumor microenvironmental constraints that affect cell trafficking and persistence.

Therapy type segmentation elucidates differences among CAR T cell therapy, TCR T cell therapy, and TIL therapy in terms of antigen recognition, manufacturing complexity, and clinical deployment. CAR T modalities offer robust responses in hematologic malignancies and rely on engineered receptor constructs, whereas TCR therapies expand the antigen repertoire including intracellular targets, and TIL therapies leverage tumor-resident lymphocytes for solid tumor immunogenicity. Finally, manufacturing model segmentation-positioning organizations between contract manufacturing and in-house production-frames strategic choices about capital investment, control over quality systems, and the ability to scale rapidly in response to clinical or commercial demand. Each segmentation axis therefore informs prioritization of R&D investments, operational design, and market engagement strategies.

How distinct regulatory environments, payer landscapes, and manufacturing capacities across global regions drive differentiated go-to-market and supply chain strategies

Regional dynamics shape strategic priorities from clinical development through commercialization and supply chain orchestration. In the Americas, robust clinical trial infrastructure, concentrated reimbursement dialogues, and substantial manufacturing capacity favor accelerated clinical translation and early commercial launches, but cost-containment pressures and regional reimbursement variability require clear value articulation and innovative pricing strategies.

In Europe, Middle East & Africa, regulatory heterogeneity and varying health technology assessment frameworks necessitate region-specific evidence packages and payer engagement plans. The region's collaborative academic hubs and growing cell therapy manufacturing footprint provide opportunities for cross-border trial networks and shared manufacturing consortia, while reimbursement timelines often influence launch sequencing and market access pathways.

The Asia-Pacific region is characterized by rapid investment in manufacturing capacity, increasing clinical trial activity, and diverse regulatory approaches that range from expedited pathways in some jurisdictions to nascent frameworks in others. Localized production and regulatory alignment efforts can create competitive advantages, particularly for companies seeking to mitigate trade-related cost pressures and accelerate patient access. Each region thus demands tailored operational plans that reconcile regulatory expectations, payer environments, clinical capabilities, and supply chain considerations to support sustainable expansion.

Company-level competitive advantage increasingly derives from integrated capabilities spanning platform science, scalable manufacturing, and proactive payer and regulatory engagement

Key company-level insights center on capability convergence, partnership strategies, and vertical integration decisions that determine competitive positioning. Leading clinical-stage organizations are combining receptor engineering expertise with translational pipelines to broaden indication coverage, while others focus on platform robustness to support multiple product candidates. Contract development and manufacturing organizations are evolving beyond pure production roles into strategic partners offering process development, analytical services, and quality-by-design capabilities that reduce time-to-clinic for sponsors.

Strategic partnerships between developers, academic centers, and manufacturing providers are increasingly common, enabling sharing of specialized knowledge such as vector optimization, potency assays, and cryopreservation techniques. Companies that invest in modular, automated manufacturing assets and data-integrated quality systems have greater flexibility to manage different therapy types and scale production across autologous and allogeneic formats. Additionally, those that proactively engage with regulators and payers to define evidence-generation pathways gain advantage in market access negotiations.

Competitive differentiation also emerges from how companies address cost-to-serve challenges through process intensification, supply chain diversification, and innovative commercial contracting. Organizations that balance clinical differentiation with operational excellence are better positioned to transition from small-batch clinical supply to reliable commercial distribution while maintaining compliance with evolving regulatory expectations.

A pragmatic playbook for leadership to align manufacturing automation, supply chain diversification, evidence generation, and stakeholder engagement to accelerate translation and adoption

Industry leaders should adopt a multi-pronged approach that aligns scientific ambition with pragmatic operational execution. First, prioritize investments in manufacturing automation and closed-system process development to reduce variability, lower labor dependency, and compress turnaround times. This operational foundation enables more consistent product quality and supports flexible responses to demand fluctuations.

Second, diversify supplier networks for critical inputs and implement strategic inventory policies to mitigate exposure to trade volatility and tariff-driven cost shifts. Simultaneously, evaluate nearshoring or regionalization of key production steps to reduce logistical complexity and improve responsiveness to regional markets. Third, pursue evidence-generation strategies that blend randomized data with real-world outcomes and registry-driven longitudinal follow-up to meet both regulatory and payer requirements for durable benefit.

Fourth, cultivate partnerships across academic, clinical, and manufacturing ecosystems to leverage external capabilities while retaining strategic control over core platform technologies. Fifth, engage early and iteratively with regulatory authorities and payers to define trial endpoints, health-economic models, and reimbursement mechanisms that align clinical value with sustainable pricing. Finally, strengthen commercial capabilities by developing outcome-based contracting frameworks and by building clinical support programs that facilitate adoption in diverse care settings. Together, these recommendations provide a roadmap to manage complexity while accelerating patient access and commercial viability.

A transparent, triangulated methodology combining expert interviews, clinical and regulatory documentation, and manufacturing process analysis to ensure robust and actionable insights

The research underpinning this executive summary synthesizes primary and secondary sources using a triangulated approach to ensure analytical rigor and relevance. Primary inputs included structured interviews with clinical investigators, manufacturing executives, and regulatory consultants, complemented by advisory sessions with payers and hospital administrators to capture operational and reimbursement perspectives. These qualitative inputs were systematically mapped against public regulatory filings, peer-reviewed literature, and industry disclosures to validate trends and identify divergences between claimed capabilities and observed operational performance.

Data analysis integrated process-level insights from manufacturing workshops with trial design and endpoint evaluations drawn from clinical registries and published studies. Where possible, methodological triangulation was applied by cross-referencing interview findings with documentary evidence and expert panel feedback. Quality control procedures included independent review of thematic findings, validation of technical assertions by subject-matter experts, and iterative refinement based on stakeholder responses. This layered approach ensured that conclusions reflect both the current state of technology and pragmatic operational constraints encountered in real-world deployment.

Synthesis of scientific promise and operational imperatives demonstrating that sustainable commercialization of T-cell therapies requires integrated technical, regulatory, and commercial execution

T-cell therapies occupy a transformative space in modern medicine, offering potentially durable solutions across oncology, infectious disease, and autoimmune indications. The field is simultaneously enabling clinical breakthroughs and confronting supply chain, manufacturing, and reimbursement realities that will determine the pace of patient access. Strategic decisions about cell source, therapeutic modality, manufacturing model, and regional expansion will be decisive for organizations aiming to translate scientific promise into lasting clinical and commercial impact.

Stakeholders who align technical innovation with operational scalability, regulatory foresight, and payer-centric evidence generation will derive competitive advantage. Conversely, those who underestimate the integration challenges across clinical, manufacturing, and commercial domains risk delayed launches and constrained uptake. In sum, the pathway to sustainable growth in T-cell therapy requires both continued scientific ingenuity and disciplined execution across the entire value chain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in dual-target CAR T-cell therapies improving tumor specificity and safety profiles
  • 5.2. Integration of gene editing technologies like CRISPR to enhance T-cell persistence and efficacy
  • 5.3. Strategic partnerships between biotech startups and pharma giants to accelerate T-cell therapy commercialization
  • 5.4. Emergence of point-of-care manufacturing platforms to reduce CAR T-cell production times and costs
  • 5.5. Expansion of T-cell therapies into autoimmune and infectious disease indications beyond oncology pipelines
  • 5.6. Development of next-generation switchable CAR T-cells enabling controlled activation to mitigate cytokine release syndrome
  • 5.7. Increasing use of artificial intelligence and machine learning in optimizing T-cell manufacturing and patient selection
  • 5.8. Regulatory landscape evolution enabling accelerated approval pathways for T-cell therapies with real-world evidence support
  • 5.9. Adoption of universal donor T-cell platforms using genome editing to prevent graft-versus-host disease risks

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. T-Cell Therapy Market, by End User

  • 8.1. Hospital
  • 8.2. Research Institute
  • 8.3. Specialty Clinic

9. T-Cell Therapy Market, by Cell Source

  • 9.1. Allogeneic
  • 9.2. Autologous

10. T-Cell Therapy Market, by Indication

  • 10.1. Autoimmune Diseases
    • 10.1.1. Multiple Sclerosis
    • 10.1.2. Psoriasis
    • 10.1.3. Rheumatoid Arthritis
  • 10.2. Infectious Diseases
    • 10.2.1. Hepatitis B
    • 10.2.2. Hepatitis C
    • 10.2.3. HIV
  • 10.3. Oncology
    • 10.3.1. Leukemia
    • 10.3.2. Lymphoma
    • 10.3.3. Multiple Myeloma
    • 10.3.4. Solid Tumors
      • 10.3.4.1. Breast Cancer
      • 10.3.4.2. Lung Cancer
      • 10.3.4.3. Melanoma

11. T-Cell Therapy Market, by Therapy Type

  • 11.1. CAR T Cell Therapy
  • 11.2. TCR T Cell Therapy
  • 11.3. TIL Therapy

12. T-Cell Therapy Market, by Manufacturing Model

  • 12.1. Contract Manufacturing
  • 12.2. In-House Manufacturing

13. T-Cell Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. T-Cell Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. T-Cell Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. Kite Pharma, Inc.
    • 16.3.3. Bristol-Myers Squibb Company
    • 16.3.4. Janssen Biotech, Inc.
    • 16.3.5. Gilead Sciences, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL T-CELL THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. T-CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL T-CELL THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 330. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 332. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 335. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 336. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 337. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 339. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 340. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 341. GLOBAL T-CELL THERAPY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 342. GLOBAL T-CELL THERAPY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 343. ASEAN T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. ASEAN T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. ASEAN T-CELL THERAPY MARKET SIZE, BY END USER, 2018-